Mark J. Ratain to Fluorouracil
This is a "connection" page, showing publications Mark J. Ratain has written about Fluorouracil.
Connection Strength
1.710
-
Phase I and pharmacokinetic study of 24-hour infusion 5-fluorouracil and leucovorin in patients with organ dysfunction. Ann Oncol. 2003 Jul; 14(7):1142-7.
Score: 0.195
-
Correspondence re: Raida, M. et al., prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls. Clin Cancer Res. 2002 May; 8(5):1314; author reply 1315-6.
Score: 0.180
-
Estimation of the effect of food on the disposition of oral 5-fluorouracil in combination with eniluracil. Cancer Chemother Pharmacol. 2002 May; 49(5):398-402.
Score: 0.177
-
Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies. Cancer. 2001 Sep 15; 92(6):1567-76.
Score: 0.172
-
5-fluorouracil pharmacokinetics: causes for variability and strategies for modulation in cancer chemotherapy. Cancer Invest. 1999; 17(7):494-506.
Score: 0.143
-
Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer. J Clin Oncol. 1996 May; 14(5):1663-71.
Score: 0.118
-
Circadian variation in plasma 5-fluorouracil concentrations during a 24 hour constant-rate infusion. BMC Cancer. 2015 Feb 18; 15:69.
Score: 0.109
-
Pharmacogenetics and pharmacogenomics of anticancer agents. CA Cancer J Clin. 2009 Jan-Feb; 59(1):42-55.
Score: 0.071
-
A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine. Ann Oncol. 2004 Nov; 15(11):1705-11.
Score: 0.053
-
Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer. Clin Cancer Res. 2002 Apr; 8(4):1042-8.
Score: 0.045
-
Dear doctor: we really are not sure what dose of capecitabine you should prescribe for your patient. J Clin Oncol. 2002 Mar 15; 20(6):1434-5.
Score: 0.044
-
Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer. J Clin Oncol. 2002 Jan 15; 20(2):582-7.
Score: 0.044
-
Pharmacogenetic study in gastric cancer patients treated with adjuvant fluorouracil/leucovorin or epirubicin/cisplatin/fluorouracil before and after chemoradiation on CALGB 80101 (Alliance). Pharmacogenet Genomics. 2021 12 01; 31(9):215-220.
Score: 0.044
-
Pharmacogenetics: a tool for individualizing antineoplastic therapy. Clin Pharmacokinet. 2000 Nov; 39(5):315-25.
Score: 0.040
-
Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance). Clin Cancer Res. 2021 01 01; 27(1):267-275.
Score: 0.040
-
Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer. Clin Cancer Res. 1999 Feb; 5(2):291-8.
Score: 0.036
-
Simultaneous determination of 5-fluorouracil and uracil by high-performance liquid chromatography using four serial columns. J Chromatogr B Biomed Sci Appl. 1998 Dec 11; 720(1-2):245-50.
Score: 0.035
-
Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer. J Clin Oncol. 1998 Apr; 16(4):1450-7.
Score: 0.034
-
Phase I study of treatment with oral 13-cis-retinoic acid, subcutaneous interferon alfa-2a, cisplatin, and 24-hour infusion 5-fluorouracil/leucovorin. Cancer Chemother Pharmacol. 1997; 39(3):227-32.
Score: 0.031
-
Effects of vascular endothelial growth factor signaling inhibition on human erythropoiesis. Oncologist. 2013; 18(8):965-70.
Score: 0.024
-
Unsupported off-label chemotherapy in metastatic colon cancer. BMC Health Serv Res. 2012 Dec 29; 12:481.
Score: 0.023
-
Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck. J Clin Oncol. 1998 Feb; 16(2):735-44.
Score: 0.008
-
Thymidylate synthase expression and response to neoadjuvant chemotherapy in patients with advanced head and neck cancer. J Natl Cancer Inst. 1997 Feb 19; 89(4):308-13.
Score: 0.008
-
Amonafide: An active agent in the treatment of previously untreated advanced breast cancer--a cancer and leukemia group B study (CALGB 8642). Clin Cancer Res. 1995 Jul; 1(7):699-704.
Score: 0.007
-
5-Fluorouracil, hydroxyurea and escalating doses of iododeoxyuridine with concomitant radiotherapy for malignant gliomas: a clinical and pharmacologic analysis. Ann Oncol. 1993 Aug; 4(7):591-5.
Score: 0.006
-
Cisplatin, fluorouracil, and leucovorin augmented by interferon alfa-2b in head and neck cancer: a clinical and pharmacologic analysis. J Clin Oncol. 1993 Feb; 11(2):360-8.
Score: 0.006
-
5-Fluorouracil, leucovorin, hydroxyurea, and escalating doses of continuous-infusion cisplatin with concomitant radiotherapy: a clinical and pharmacologic study. Cancer Chemother Pharmacol. 1992; 29(3):178-84.
Score: 0.005
-
A phase I study of cisplatin, 5-fluorouracil and leucovorin with escalating doses of hydroxyurea in chemotherapy naive patients. Eur J Cancer. 1991; 27(2):217-8.
Score: 0.005
-
A randomized study of inpatient versus outpatient continuous infusion chemotherapy for patients with locally advanced head and neck cancer. Cancer. 1989 Jan 01; 63(1):30-6.
Score: 0.004